Showing 3591-3600 of 7859 results for "".
- FDA Clears CellFX System for the Treatment of SHhttps://practicaldermatology.com/news/fda-clears-cellfx-system-for-the-treatment-of-sh/2461358/The U.S. Food and Drug Administration (FDA) granted Pulse Bioscience’s CellFX System (FDA) 510(k)marketing clearance for the treatment of sebaceous hyperplasia in patients with Fitzpatrick skin types I-II. This specific indication clearance enhances the CellFX
- Lauren Miller, MPAS, PA-C Begins Term as SDPA Presidenthttps://practicaldermatology.com/news/lauren-miller-mpas-pa-c-begins-term-as-sdpa-president/2461267/Lauren Miller, MPAS, PA-C is president of the Society of Dermatology Physician Assistants Board of Directors. Ms. Miller, a DermPA™ with Dermatology Specialists in Gadsden, AL, will serve a one-year term leading the nine-member elected board. “I am honored and humbled t
- Message from ASLMS President Dr. Paul M. Friedmanhttps://practicaldermatology.com/news/message-from-aslms-president-dr-paul-m-friedman/2461221/Dr. Paul M. Friedman, president of the American Society for Laser Medicine and Surgery (ASLMS), is calling on members to expand philanthropic programs that can help change lives with lasers. “In the coming year, I will be looking to the membership to bring their talents forwa
- PatientFi Expands Co-marketing Agreement with Allerganhttps://practicaldermatology.com/news/patientfi-expands-co-marketing-agreement-with-allergan/2461148/PatientFi® is expanding its co-marketing agreement with Allergan Aesthetics, an AbbVie company, to provide financing options for patients interested in treatments such as BOTOX® Cosmetic (onabotulinumtoxinA), JUVÉDERM®Collection of Fillers, Natrelle® breast i
- Light Therapy Fast-tracks Healing of Skin Damage from Brachytherapyhttps://practicaldermatology.com/news/light-therapy-fast-tracks-healing-of-skin-damage-from-brachytherapy/2461055/Light therapy may accelerate the healing of skin damage from radiation therapy by up to 50 percent, according to a recent University at Buffalo-led study. Photobiomodulation – a form of low-dose light therapy –lowered the severity of skin damage from radionecrosis, reduced i
- Strand Therapeutics Scores Two Grants to Advance Programmable, Long-Lasting mRNA Therapeutics for Melanoma and Breast Cancerhttps://practicaldermatology.com/news/strand-therapeutics-scores-two-grants-to-advance-programmable-long-lasting-mrna-therapeutics-for-melanoma-and-breast-cancer/2460881/Strand Therapeutics was awarded two Phase I Small Business Innovation Research (SBIR) grants from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) to develop mRNA-based therapeutics for melanoma and triple negative breast cancer (TNBC). The total fund
- Robert Moccia Takes the Helm at STRATA Skin Scienceshttps://practicaldermatology.com/news/robert-moccia-takes-the-helm-at-strata-skin-sciences/2460705/Robert (Bob) Moccia is the new President and Chief Executive Officer and a member of the board of STRATA Skin Sciences, Inc. He replaces Dolev Rafaeli, PhD, who stepped down last month. “I am confident that STRATA has the technology
- In Review: VCS Virtual Format Hailed as a Successhttps://practicaldermatology.com/news/in-review-vcs-virtual-format-hailed-a-success/2460601/After a decade and a half of bringing topline aesthetic education to Las Vegas, VCS went virtual this fall. “While it wasn't live—it was virtual—I knew it was absolutely fantastic,” says meeting
- Where is the Hydroquinone? Regulatory Change Hinders Accesshttps://practicaldermatology.com/news/where-is-the-hydroquinone-regulatory-change-hinders-access/2460586/Changes to FDA regulations implemented as part of the CARES Act this spring have left dermatologists and their patients scrambling to access hydroquinone. Although access is hindered, it is not cut off. “I think most people at this point are familiar with the CARES Act. What they
- With New Funding, Turn Therapeutics Will Launch Phase 4 Study of AD Drughttps://practicaldermatology.com/news/with-new-funding-turn-therapeutics-will-launch-phase-4-study-of-ad-drug/2460162/Turn Therapeutics has closed its fully-subscribed series B financing. The capital raised will fund a large-scale, pre-launch, phase 4 trial for AtopX Eczema Emulsion, with enrollment scheduled to begin in Q1 2020. The series B financing will also support advancement of additional i